Tafolecimab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Tafolecimab Usage And Synthesis

Uses

Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia[1].

References

[1] Y Cui, et al. Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects.European Heart Journal, Volume 41, Issue Supplement_2, November 2020.

Tafolecimab(2225109-03-3)Related Product Information

• Duligotuzumab
• Rinucumab
• Depatuxizumab
• Flotetuzumab
• Osocimab
• Flanvotumab
• Zamerovimab
• Vanucizumab
• Iparomlimab
• Gresonitamab